An Open-label, Randomized Phase III Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
What is the purpose of this trial?
This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.
- Pfizer Inc., U.S. Pharmaceuticals Group
- Last Updated:
- Study HIC#: